Introduction
============

Lung cancer is the leading cause of cancer deaths worldwide for both men and women[@B1]. To determine optimal therapeutic strategy for lung cancer patients, accurate staging is essential.

Mediastinoscopy is often considered as gold standard procedure for the mediastinal staging of lung cancer[@B2]. However, a prospective cohort study with 190 lung cancer patients found that diagnostic performance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was comparable with that of mediastinoscopy[@B3]. A meta-analysis of 11 observational studies which compared EBUS-TBNA with mediastinoscopy also showed similar sensitivity and specificity[@B4].

Computed tomography (CT) and ^18^F-fluorodeoxyglucose (FDG) positron emission tomography-CT (PET-CT) are standard imaging modalities for staging of lung cancer. However, chest CT or PET-CT have limited reliability for the sensitivity or specificity of lymph node staging[@B5][@B6][@B7][@B8][@B9]. Previous studies reported that the sensitivity and specificity of chest CT in identifying lymph node metastases were 55% and 81%, respectively[@B10]. In comparison to CT imaging, PET-CT had shown to have better sensitivity and specificity, 77% and 86% respectively[@B10]. However, in patients with granulomatous disease such as sarcoidosis, concurrent infectious and inflammatory disease such as tuberculosis, pneumonia and interstitial lung disease (ILD), PET-CT has been shown to increase the rates of false-positive malignancy in mediastinal lymph nodes[@B11][@B12].

Therefore, in the present study, we investigated various benign causes of false-positive lymph node including anthracosis or anthracofibrosis, pneumoconiosis, old or active tuberculosis, ILD and other infectious conditions including pneumonia on chest CT or PET-CT using EBUS-TBNA.

Materials and methods
=====================

1. Patients
-----------

Data were collected from lung cancer patients who underwent EBUS-TBNA for suspicious lymph node involvement by chest CT or PET-CT from May 2009 to December 2012 in Seoul St. Mary\'s Hospital. The diagnosis of lymph node involvement was determined by EBUS-TBNA. True-positive was defined as a diagnosis of lymph node metastasis from lung cancer. True-negative was defined as a diagnosis of benign lymphoid tissue. We also defined false-positive group as patients with negative result of malignancy from EBUS-TBNA although chest CT or PET-CT were positive.

Anthracosis or anthracofibrosis were defined by bronchoscopic findings demonstrating black-brown pigment lining the endobronchial mucosa with or without fibrotic distortion/narrowing of the bronchus. Diagnosis of pneumoconiosis includes chest imaging consistent with pneumoconiosis plus occupational inhalation exposure history of sufficient amount and latency to coal or silica dust. Previous history of tuberculosis was defined as old tuberculosis. If lung cancer was concomitantly diagnosed with tuberculosis, it was defined as active tuberculosis. ILD was defined by typical radiological findings with symptoms and signs of ILD.

All subjects provided written informed consent for the procedure, and the study protocol was approved by the Institutional Review Board of Seoul St. Mary\'s Hospital, The Catholic University of Korea (IRB approval number: KC16RISI0733).

2. EBUS-TBNA
------------

The EBUS-TBNA was done by two experts using a flexible linear (convex) ultrasound bronchoscopy system (Olympus, Tokyo, Japan). The procedure was performed with the patient under conscious sedation by midazolam, and local anesthesia (lidocaine) was applied. After scanning the mediastinal lymph node, each target lymph node was aspirated at least 3 times with a 22-gauge needle. Lymph node location was classified according to the International Association for the Study of Lung Cancer (IASLC) lymph node map[@B13]. The aspirated tissue was fixed promptly with 95% alcohol, and stained using Papanicolaou. An expert lung pathologist (K.Y. Lee) performed the cytopathological examinations.

3. Chest CT
-----------

Multi-detector computed tomography (SOMATOM Definition; Siemens, Erlangen, Germany and Discovery CT750 HD; GE Healthcare, Waukesha, WI, USA) was performed using a slice thickness of 1 mm reconstructed at 0.75-mm intervals with contrast injection by a mechanical injector at a rate of 3 mL/sec, for a total dose of 100 mL. Axial, sagittal and coronal images were reconstructed at 3-mm interval and were transferred to a PACS workstation (Maroview; Marotech, Seoul, Korea). All abnormal findings on chest CT were reviewed in lymph node stations according to the guidelines of the IASLC[@B13]. On chest CT, positive lymph node was defined as short diameter longer than 1 cm[@B14].

4. PET-CT
---------

Patients were fasted for at least 6 hours before PET-CT scanning. Scanning was done 60 minutes later after FDG injection (5.5--7.4 MBq/kg). None of the patients had a blood glucose level higher than 130 mg/dL before injection. No intravenous contrast agent was administered. Studies were acquired on combined PET-CT in-line systems, either Biograph Duo or Biograph Truepoint (Siemens Medical Solutions, Knoxville, TN, USA). The maximum standardized uptake value (SUV) was used to define positive lymph node on PET-CT, and the SUV was obtained by locating a region of interest on a lesion. A maximum SUV \>2.5 on a lymph node was interpreted as positive[@B15].

5. Statistical analysis
-----------------------

The descriptive statistics were calculated and are presented as number (percentage) for categorical variables, and the mean±SD and median (range) for continuous variables. Differences between the false-positive and true-positive group were compared using the Wilcoxon rank-sum test for continuous variables and the chi-square or Fisher exact test for categorical variables. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of chest CT and PET-CT were measured for the detection of mediastinal lymph node metastases. The receiver operating characteristic (ROC) curve and the Youden index identified an optimal age cut-off value for mediastinal lymph node metastases. Univariate and multivariable logistic regressions analyses were performed to determine odds ratios (ORs) for identify independent predictors of false-positive. Analyses were conducted using the SAS statistical software version 9.4 (SAS Institute Inc., Cary, NC, USA). The significance level for statistical tests were set at α=0.05 (two-tailed).

Results
=======

1. Patients\' characteristics
-----------------------------

Among the 247 patients who underwent EBUS-TBNA, male patients were 199 (80.6%), and mean and median age was 64.9 and 66.0, respectively ([Table 1](#T1){ref-type="table"}). Predominant histologic type was adenocarcinoma (116 cases, 47.0%). The number of nodes sampled per patients was one in 123 (49.8%), two in 107 (43.3%) and three in 17 (6.9%). Staging workup indicated that 95 patients (49.0%) were classified as stage IV in non-small cell lung cancer, and 39 (73.6%) were extensive disease in small cell lung cancer. Mediastinal lymph node metastases were confirmed by EBUS-TBNA in 258 nodal stations from total 388 lymph nodes.

2. Diagnostic performance of chest CT and/or PET-CT according to lymph node
---------------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} presents sensitivity, specificity, PPV, NPV, accuracy, and area under the curve (AUC) of chest CT and/or PET-CT. Sensitivity was the highest in chest CT or PET-CT group, but this group presented the lowest specificity. Chest CT and PET-CT group showed the highest specificity, but the specificity was only 54.6%. The false-positive rate according to lymph nodes was 55.4% in chest CT, 87% in PET-CT, 45.4% in chest CT and PET-CT, and 93.5% in chest CT or PET-CT group ([Figure 1](#F1){ref-type="fig"}).

3. Factors associated with false-positive lymph node according to patients
--------------------------------------------------------------------------

False-positive lymph nodes depending on the lymph node location was shown according to IASLC ([Table 3](#T3){ref-type="table"}) and the demographic differences between the false-positive group and the true-positive group are presented in [Table 4](#T4){ref-type="table"}. The false-positive patients had significantly higher mean and median age than the true-positive patients (mean age, 68.2±9.5 vs. 63.9±10.0, p=0.004; median age, 69.5 \[45.0--87.0\] vs. 65.0 \[33.0--85.0\], p=0.004). According to the histologic type, false-positive rate was the highest in patients with squamous cell carcinoma, and the lowest in small cell carcinoma. Except old or active tuberculosis, other benign conditions such as anthracosis or anthracofibrosis, ILD and pneumonia showed a higher tendency of false-positive rate, but were not statistically significant. Patients with pneumoconiosis had higher false-positive rate than those without pneumoconiosis.

4. Univariate and multivariate analyses of false-positive patients
------------------------------------------------------------------

Logistic regression analysis of clinicopathological parameters for the prediction of false-positive patients with lung cancer is shown in [Table 5](#T5){ref-type="table"}. As mentioned above, older age was associated with increased risk of having a false-positive result on chest CT or PET-CT. We determined the optimal discriminator value for age using ROC curve analysis ([Figure 2](#F2){ref-type="fig"}). AUC was the highest (0.624) when patients were divided into two groups according to age 65. Logistic regression analysis revealed that false-positive rate was significantly higher (OR, 2.21; 95% confidence interval \[CI\], 1.12--4.36; p=0.022) in the older age group ([Table 5](#T5){ref-type="table"}).

Histology of squamous cell carcinoma indicated significantly high false-positive rate (OR, 2.84; 95% CI, 1.48--5.43; p=0.002), whereas small cell carcinoma showed significantly low false-positive rate (OR, 0.18; 95% CI, 0.06--0.55; p=0.003). Patients with pneumoconiosis also showed significantly high false-positive rate (OR, 6.33; 95% CI, 1.34--29.96; p=0.020).

Discussion
==========

The aim of the present study was to examine the possible causes of false-positive lymph node detected in chest CT or PET-CT in patients with lung cancer by using EBUS-TBNA. We found that older age, histologic type of squamous cell carcinoma and benign condition such as pneumoconiosis were related with false-positive lymph node.

In the present study, older age was identified as a risk factor for false-positive lymph node. Possible explanations include many age-associated changes due to less robust immune response in the respiratory system. Many complex changes in both the innate and adaptive immune systems might contribute to increase susceptibility to infections[@B16]. Cumulative episodes of previous infectious or inflammatory lung conditions might also be the causes of increasing tendency of false-positive lymph node in elderly patients.

Previous studies indicated that patients with adenocarcinoma had low FDG uptake compared to those with squamous cell carcinoma[@B17][@B18][@B19]. Hwangbo et al.[@B20] reported that higher rate of lymph node metastasis was detected in patients with adenocarcinoma compared to those with squamous cell carcinoma, although PET-CT scan findings were negative. According to a study by Lu et al.[@B21], PET-CT showed higher false positivity in squamous cell carcinoma group than in adenocarcinoma group. These previous results correspond well with the present study that patients with squamous cell carcinoma had more false-positive lymph node on chest CT and PET-CT than those with adenocarcinoma. A possible explanation for the differences between squamous cell carcinoma and adenocarcinoma is that most of squamous cell carcinomas are central bronchogenic carcinoma and are usually accompanied with obstructive pneumonia and atelectasis, and this may activate macrophages and inflammatory cells which could cause reactive hyperplasia of lymph nodes[@B21].

If histologic findings of specimens from EBUS-TBNA are not related to tumors, benign findings include reactive lymphadenitis, anthracotic pigmentations with or without fibrosis, and granulomatous inflammation.

Interestingly, univariate and multivariate analyses indicated that small cell carcinoma had significantly low false-positive rate compared with adenocarcinoma and squamous cell carcinoma. Moreover, squamous cell carcinoma showed significantly high false-positive rate compared with adenocarcinoma and small cell carcinoma. Considering these findings, one might think that small cell carcinoma and adenocarcinoma could metastasize although chest CT and PET-CT could not detect lymph node metastasis[@B20].

Metser and Even-Sapir[@B22] have reported that inflammatory lesions in the tracheobronchial tree (tracheitis and infected bronchiectasis), lung (viral, bacterial, fungal infection, abscess, ILD, cryptogenic organizing pneumonia, lipoid pneumonia, Langerhans cell histiocytosis, vasculitis, sarcoidosis, Wegner\'s granulomatosis, and inhalational lung disease), and pleura (empyema) induces false-positive findings due to increased uptake of FDG in the chest. Radiologic findings of bronchial obstructive lesion and mediastinal lymph nodes in bronchial anthracofibrosis could mimic cancer[@B23]. In the present study, patients with pneumoconiosis had higher false-positive rate than those without pneumoconiosis. However, patients with anthracosis or anthracofibrosis, ILD and pneumonia showed statistically insignificant. The present study investigated old or active tuberculosis which includes pulmonary and extrapulmonary tuberculosis. The incidence of extrapulmonary tuberculosis showed 11%--17% of total tuberculosis in Korea[@B24]. Tuberculous lymphadenopathy is one of the extrapulmonary tuberculosis manifestation. Therefore, limited number of patients as well as total tuberculosis cases studied in the present study can explain the reason that tuberculosis was not related with false-positive lymph node in this study.

The present study has several limitations. First, this is a retrospective study with a relatively small number of patients. Second, surgical confirmation for mediastinal lymph node was limited in the present study and only 28 patients underwent surgery. Among them, two patients\' 4R lymph nodes were upstaged from N0 to N2. Therefore, there can be another false-negative results of EBUS-TBNA. Third, specificity of imaging modalities from the present study was lower than previous reports. Previous studies have reported that specificity of chest CT and PET-CT is 66%--90% and 67%--94%, respectively[@B2][@B10]. This discrepancy may be related to different selection criteria. The present study defined positive lymph node involvement as short diameter longer than 10 mm on axial image of CT scan, and maximum FDG uptake above 2.5 on PET-CT. Different studies have performed using different criteria for the definition of lymph node positivity on chest CT and PET-CT. In addition, the present study performed EBUS-TBNA when there was positive lymph node finding on either chest CT or PET-CT.

In conclusion, the present study suggests that lung cancer staging should be performed more carefully when a patient has clinically benign lymph node characteristics including older age, histologic type of squamous cell carcinoma and benign lung conditions.
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###### Baseline characteristics of the 247 lung cancer patients

![](trd-81-339-i001)

  Variable                   No. (%) (n=247)
  -------------------------- -------------------
  Sex                        
   Male                      199 (80.6)
   Female                    48 (19.4)
  Age, yr                    
   Mean±SD                   64.9±10.0
   Median (range)            66.0 (33.0--87.0)
  Histology                  
   Adenocarcinoma            116 (47.0)
   Squamous cell carcinoma   67 (27.1)
   Large cell carcinoma      5 (2.0)
   Small cell carcinoma      53 (21.5)
   Others                    6 (2.4)
  Stage                      
   NSCLC (n=194)             
    IA                       6 (3.1)
    IB                       3 (1.5)
    IIA                      9 (4.6)
    IIB                      2 (1.0)
    IIIA                     47 (24.2)
    IIIB                     32 (16.5)
    IV                       95 (49.0)
   SCLC (n=53)               
    Limited disease          14 (26.4)
    Extensive disease        39 (73.6)

NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer.

###### Diagnostic performance of chest CT, PET-CT, chest CT and/or PET-CT according to lymph node positivity by EBUS-TBNA

![](trd-81-339-i002)

                        Sensitivity (95% CI, %)   Specificity (95% CI, %)   PPV (95% CI, %)     NPV (95% CI, %)       Accuracy (95% CI, %)   AUC (95% CI)
  --------------------- ------------------------- ------------------------- ------------------- --------------------- ---------------------- ----------------------
  Chest CT              88.8 (84.3--92.3)         44.6 (35.9--53.6)         76.1 (70.9--80.8)   66.7 (55.8--76.4)     74.0 (69.3--78.3)      0.667 (0.618--0.714)
  PET-CT                99.2 (97.1--99.9)         13.0 (7.6--20.3)          69.9 (64.8--74.6)   88.9 (65.3--98.6)     70.8 (65.9--75.3)      0.561 (0.509--0.612)
  Chest CT and PET-CT   85.7 (80.8--89.7)         54.6 (45.7--63.4)         78.9 (73.7--83.6)   65.7 (56.0--74.6)     75.3 (70.7--79.5)      0.701 (0.653--0.747)
  Chest CT or PET-CT    100.0 (98.5--100.0)       6.5 (2.8--12.4)           68.5 (63.5--73.2)   100.0 (63.1--100.0)   69.2 (64.2--73.8)      0.533 (0.480--0.584)

CT: computed tomography; PET-CT: positron emission tomography-CT; EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value; AUC: area under the curve.

###### False-positive lymph nodes depending on the lymph node location according to IASLC

![](trd-81-339-i003)

  Lymph node location                                                 No. of lymph nodes studied   No. of false-positive lymph nodes   False-positive rate (%)
  ------------------------------------------------------------------- ---------------------------- ----------------------------------- -------------------------
  Right lower cervical, supraclavicular and sternal notch node (1R)   2                            2                                   100.0
  Right upper paratracheal node (2R)                                  6                            2                                   33.3
  Right lower paratracheal node (4R)                                  141                          44                                  31.2
  Right hilar node (10R)                                              12                           4                                   33.3
  Right interlobar node (11R)                                         10                           1                                   10.0
  Right lobar lymph node (12R)                                        2                            1                                   50.0
  Subcarinal node (7)                                                 157                          61                                  38.9
  Left lower cervical, supraclavicular, and sternal notch node (1L)   1                            0                                   0.0
  Left upper paratracheal node (2L)                                   2                            0                                   0.0
  Left lower paratracheal node (4L)                                   48                           13                                  27.1
  Left hilar node (10L)                                               4                            2                                   50.0
  Left interlobar node (11L)                                          2                            0                                   0.0
  Retrotracheal lymph node (3P)                                       1                            0                                   0.0
  Total No. of lymph nodes                                            388                          130                                 33.5

IASLC: International Association for the Study of Lung Cancer.

###### Factors associated with false-positive patients of chest CT and PET-CT
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  Variable                          False-positive (n=58)   True-positive (n=189)   p-value
  --------------------------------- ----------------------- ----------------------- ---------
  Sex                                                                               
   Male                             49 (84.5)               150 (79.4)              0.389
   Female                           9 (15.5)                39 (20.6)               
  Age, yr                                                                           
   Mean±SD                          68.2±9.5                63.9±10.0               0.004
   Median (range)                   69.5 (45.0--87.0)       65.0 (33.0--85.0)       0.004
   \<65                             16 (27.6)               92 (48.7)               0.005
   ≥65                              42 (72.4)               97 (51.3)               
  Histology                                                                         
   Adenocarcinoma                   25 (43.1)               91 (48.1)               \<0.001
   Squamous cell carcinoma          26 (44.8)               41 (21.7)               
   Large cell carcinoma             1 (1.7)                 4 (2.1)                 
   Small cell carcinoma             4 (6.9)                 49 (25.9)               
   Others                           2 (3.4)                 4 (2.1)                 
  Anthracosis or anthracofibrosis                                                   
   Absence                          52 (89.7)               177 (93.7)              0.262
   Presence                         6 (10.3)                12 (6.3)                
  Pneumoconiosis                                                                    
   Absence                          53 (91.4)               186 (98.4)              0.019
   Presence                         5 (8.6)                 3 (1.6)                 
  Old or active tuberculosis                                                        
   Absence                          47 (81.0)               147 (77.8)              0.597
   Presence                         11 (19.0)               42 (22.2)               
  ILD                                                                               
   Absence                          52 (89.7)               173 (91.5)              0.660
   Presence                         6 (10.3)                16 (8.5)                
  Pneumonia                                                                         
   Absence                          51 (87.9)               167 (88.4)              0.929
   Presence                         7 (12.1)                22 (11.6)               

Values are presented as number (%) or mean±SD.

CT: computed tomography; PET-CT: positron emission tomography-CT; ILD: interstitial lung disease.

###### Logistic regression analysis of clinicopathological parameters for the prediction of false-positive patients with lung cancer
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  Variable                                                                                              Univariate analysis   Multivariate analysis                        
  ----------------------------------------------------------------------------------------------------- --------------------- ----------------------- -------------------- -------
  Age, yr                                                                                                                                                                  
   \<65                                                                                                 1.00                  0.005                   1.00                 0.022
   ≥65                                                                                                  2.49 (1.31--4.73)                             2.21 (1.12--4.36)    
  Histology                                                                                                                                                                
   Adenocarcinoma vs. squamous cell carcinoma, large cell carcinoma, small cell carcinoma, and others   0.82 (0.45--1.48)     0.501                   \-                   \-
   Squamous cell carcinoma vs. adenocarcinoma, large cell carcinoma, small cell carcinoma, and others   2.93 (1.57--5.47)     0.001                   2.84 (1.48--5.43)    0.002
   Large cell carcinoma vs. adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and others   0.81 (0.09--7.41)     0.853                   \-                   \-
   Small cell carcinoma vs. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others   0.21 (0.07--0.62)     0.004                   0.18 (0.06--0.55)    0.003
   Others vs. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, small cell carcinoma       1.65 (0.30--9.26)     0.568                   \-                   \-
  Anthracosis or anthracofibrosis                                                                                                                                          
   Absence                                                                                              1.00                  0.310                   \-                   \-
   Presence                                                                                             1.70 (0.61--4.76)                             \-                   
  Pneumoconiosis                                                                                                                                                           
   Absence                                                                                              1.00                  0.018                   1.00                 0.020
   Presence                                                                                             5.85 (1.35--25.27)                            6.33 (1.34--29.96)   
  Old and active tuberculosis                                                                                                                                              
   Absence                                                                                              1.00                  0.598                   \-                   \-
   Presence                                                                                             0.82 (0.39--1.72)                             \-                   
  ILD                                                                                                                                                                      
   Absence                                                                                              1.00                  0.661                   \-                   \-
   Presence                                                                                             1.25 (0.46--3.35)                             \-                   
  Pneumonia                                                                                                                                           \-                   
   Absence                                                                                              1.00                  0.929                   \-                   \-
   Presence                                                                                             1.04 (0.42--2.58)                             \-                   

OR: odds ratio; CI: confidence interval; ILD: interstitial lung disease.
